Accenture reveals data science project for paediatric leukaemia
Accenture Applied Intelligence announced a new data and analytics approach to manage and derive insights from paediatric acute myeloid leukaemia (AML) genomic data, with the potential to improve precision medicine.
The large-scale project, undertaken in collaboration with researchers and clinicians from Fred Hutchinson Cancer Research Center (Fred Hutch) and the Target Padiatric AML (TpAML) computational working group aims to enable paediatric oncology physicians and researchers to better analyse patient clinical trial and genetic data.
Accenture data scientists, in collaboration with investigators from TpAML led by Dr Soheil Meshinchi at Fred Hutch, collected and standardised genomic and clinical data from over 2,000 children with AML who had been treated in clinical trials.
Read more: http://www.pharmatimes.com/news/accenture_reveals_data_science_project_for_paediatric_leukaemia_1351632
The large-scale project, undertaken in collaboration with researchers and clinicians from Fred Hutchinson Cancer Research Center (Fred Hutch) and the Target Padiatric AML (TpAML) computational working group aims to enable paediatric oncology physicians and researchers to better analyse patient clinical trial and genetic data.
Accenture data scientists, in collaboration with investigators from TpAML led by Dr Soheil Meshinchi at Fred Hutch, collected and standardised genomic and clinical data from over 2,000 children with AML who had been treated in clinical trials.
Read more: http://www.pharmatimes.com/news/accenture_reveals_data_science_project_for_paediatric_leukaemia_1351632
